Diagnostic and therapeutic management in patients with hypereosinophilic syndromes

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 1-2, 2011, Pages 44-52

  Helbig, Grzegorz ^a   Kyrcz Krzemień, Sławomira ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Chronic eosinophilic leukemia; Eosinophilia; FIP1L1 PDGFRA; Hypereosinophilic syndrome; Imatinib

Indexed keywords

ALEMTUZUMAB; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN; HYDROXYUREA; IMATINIB; INTERFERON; INTERLEUKIN 5; MEPOLIZUMAB; METHYLPREDNISOLONE; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; STEROID;

ADULT; AGED; ALLOTRANSPLANTATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FEMALE; GENETIC MARKER; HEART FAILURE; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; MALE; MONOTHERAPY; NEUROLOGIC DISEASE; PATHOGENESIS; PROGNOSIS; RECURRENT DISEASE; REVIEW; SKIN DISEASE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

EID: 79954459929     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1021     Document Type: Review

References (49)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975; 54: 1-27.
2. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: current concepts and treatments. Brit J Haematol. 2009; 145: 271-285.
3. Cools J, De Angelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Eng J Med. 2003; 348: 1201-1214. (Pubitemid 36359296)
4. Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117: 1292-1309.
5. Vardiman JW, Brunning RD, Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Lee Harris N, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008: 31-73.
6. Hellmann A. Myeloproliferative syndromes: diagnosis and therapeutic options. Pol Arch Med Wewn. 2008; 118: 756-760.
7. Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126: 45-49.
8. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006; 24: 147-174.
9. Klion A. How I treat hypereosinophilic syndromes. Blood. 2009; 114: 3736-3741.
10. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point of care diagnostic algorithm and treatment update. Mayo Clin Proc. 2010; 85: 158-164.
11. Butterfield JH. Interferon treatment for hypereosinophilic syndrome and systemic mastocytosis. Acta Haematol. 2005; 114: 26-40. (Pubitemid 40911570)
12. Quintás-Cardama A, Cortes J. Therapeutic options for patients with clonal and idiopathic hypereosinophilia. Expert Opin Invest Drugs. 2008; 17: 1039-1050.
13. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, restrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009; 124: 1319-1324.
14. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 105: 3038-3045. (Pubitemid 39507117)
15. Helbig G, Moskwa A, Hus M, et al. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript-results of Polish multicentre study. Hematol Oncol. 2010; 28: 93-97.
16. Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin N Am. 2007; 27: 333-355. (Pubitemid 47380241)
17. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate In patients with FIP1L1-PDGFRA positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92: 1173-1179.
18. Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008; 143: 707-715.
19. Rodzaj M, Gała̧zka K, Majewski M, et al. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: Pol Arch Med Wewn. 2009; 119: 838-841.
20. Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol. 2008; 141: 200-204. (Pubitemid 351406214)
21. Helbig G, Hus M, Moskwa A, et al. Long-term remission maintenance on weekly imatinib dosage in patients with FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia. Blood 2010. 52nd Annual Meeting of American Society of Hematology, Orlando. [USA] 06-09.12.2010. abstract 4087.
22. Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia: implications for optimal dosing. Blood. 2007; 110: 3552-3556. (Pubitemid 350159620)
23. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003; 101: 4660-4666. (Pubitemid 36857718)
24. Lierman E, Michaux L, Beullens E, at al. FIP1L1-PDGFRA D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGF T674I eosinophilic leukaemia with single agent sorafenib. Leukemia. 2009; 23: 845-851.
25. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood. 2003; 102: 3456-3457. (Pubitemid 37314790)
26. Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007; 27: 389-413. (Pubitemid 47380239)
27. Cogan E, Schandene L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Eng J Med. 1994; 330: 535-538. (Pubitemid 24058956)
28. Roufosse F. Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations. Haematologica. 2009; 94: 1188-1193.
29. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Eng J Med. 1999; 341: 1112-1120. (Pubitemid 29466223)
30. Simon HU, Yousefi S, Dommann-Scherrer CC, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med. 1996; 183: 1071-1082.
31. Galimberti S, Ciabatti E, Ottimo F, et al. Cell clonality in hypereosinophilic syndrome: what pathogenic role? Clin Exp Rheumatol. 2007; 25: 17-22.
32. Helbig G, Wieczorkiewicz A, Dziaczkowska-Suszek J, et al. T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica. 2009; 94: 1236-1241.
33. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy". J Exp Med. 1994; 179: 609-618.
34. Hodges E, Krishna MT, Pickard C, Smith JL. Diagnostic role of tests for T cell receptor (TCR) genes. J Clin Pathol. 2003; 56: 1-11. (Pubitemid 36132467)
35. Ravoet M, Sibille C, Roufosse F, et al. 6q- is an early and persistent chromosomal abberation in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica. 2005; 90: 753-765. (Pubitemid 40897217)
36. Roufosse F, Schandené L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000; 109: 540-548. (Pubitemid 30415180)
37. Helbig G, Wichary R, Raźny M, et al. The proportion of CD3-CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES). Scand J Immunol. 2010; 72: 372-373.
38. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukaemia. Clin Cancer Res. 2009; 15: 368-373.
39. Rothenberg ME, Klion AD, Roufosse FE, et al.; Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008; 358: 1215-1228. (Pubitemid 351439223)
40. Jain N, Cortes J, Quintás-Cardama A, et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status. Leuk Res. 2009; 33: 837-839.
41. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome. Leuk Res. 2009; 33: 1127-1129.
42. Juvonen E, Volin L, Koponen A, Ruutu T. Allogeneic blood stem cell transplanatation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant. 2002; 119: 131-134.
43. Tefferi A, Lasho TL, Brockman SR, et al. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica. 2004; 89: 871-873. (Pubitemid 38981353)
44. Robyn J, Lemery S, McCoy JP, et al. Multilineage involvement of the fusion gene in patients with FIP1L1-PDGFRA-positive hypereosinophilic syndrome. Br J Haematol. 2005; 132: 286-292. (Pubitemid 43381535)
45. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007; 21: 1183-1188. (Pubitemid 46831806)
46. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 1998; 18: 84-87. (Pubitemid 28027887)
47. Abruzzo LV, Jaffe ES, Cotelingam JD, et al. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol. 1992; 16: 236-245.
48. Goradia A, Bayer M, Corfield D. The 8p11 myeloproliferaive syndrome: review of literature and an illustrative. Int J Clin Exp Pathol. 2008; 1: 448-456.
49. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002; 107: 101-107. (Pubitemid 34264174)